Partnership with National Kidney Foundation
("RenalytixAI" or the "Company")
Partnership with
to improve management of Early Stage Kidney Disease
Program focused on improving disease management and outcomes beginning at the primary care level
Kidney disease affects an estimated 37 million adults in the
"We must reach people early in their disease in order to slow or even stop the progression," said NKF Chief Executive Officer
NKF and RenalytixAI will collaborate for the first time in their histories on future studies to assess current care standards in early stage kidney disease, identify barriers to better care and opportunities for improvement. Long-term initiatives will be developed as the partnership unfolds.
With as many as 90 percent of the people today who have early-stage kidney disease unaware that they have the dangerous disease, scientists, investigators and clinicians are trying to understand how we can increase understanding and promote patient specific care, engagement and monitoring.
KidneyIntelX is an in vitro diagnostic platform that uses a machine learning enabled algorithm to interpret proprietary biomarkers from a simple blood draw and electronic health record features to generate a patient specific risk score for disease progression. The KidneyIntelX risk score categorizes a patient as low, intermediate or high risk for kidney disease progression and kidney failure. The individual patient's score will be integrated with risk appropriate NKF recommended clinical actions and education resources as part of a comprehensive approach to improve outcomes.
"This partnership with RenalytixAI will potentially improve kidney risk stratification, using artificial intelligence to evaluate the combination of important kidney function biomarkers and electronic health record information more accurately than measuring biomarkers alone," said NKF Chief Medical Officer
"The partnership with NKF, the leading American kidney patient advocacy organization, will allow RenalytixAI to better consider the patient perspective and leverage the educational resources of the NKF to help improve patient quality of life, reduce suffering and potentially reduce the number of patients suffering from kidney failure," said
For further information, please contact:
|
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.
About the
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning the benefits of the partnership between NKF and RenalytixAI and the ability of the partnership to help improve patient quality of life, reduce suffering and potentially reduce the number of patients suffering from kidney failure. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. The plans and objectives disclosed in the forward-looking statements may not actually be achieved, and you should not place undue reliance on these forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; RenalytixAI has only recently commercially launched KidneyIntelX; and risks relating to the impact on RenalytixAI's business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in RenalytixAI's filings with the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the